Community-Onset Bloodstream and Other Infections, Caused by Carbapenemase-Producing Enterobacteriaceae: Epidemiological, Microbiological, and Clinical Features

José Ramón Paño-Pardo,1,5,6 Beatriz López Quintana,2 Fernando Lázaro Peona,2 Guillermo Ruiz Carrascoso,2 María Pilar Romero-Gómez,2 Belén Loeches Yagüe,3 Beatriz Díaz-Pollán,1 Ana Martínez-Virto,4 Jesús Mingorance,2 Julio García Rodríguez,2 José Ramón Arribas,1 and Rosa Gómez-Gil2

1Infectious Diseases and Clinical Microbiology Unit, Department of Internal Medicine, 2Department of Microbiology, 3Infectious Diseases and Clinical Microbiology Unit, Department of Microbiology, 4Department of Emergency Medicine, Hospital Universitario La Paz-IdiPAZ, Madrid, 5Division of Infectious Diseases, Hospital Clínico Universitario “Lozano Blesa”, and 6Instituto de Investigaciones Sanitarias (IIS) de Aragón, Zaragoza, Spain

Background. Because most infections caused by carbapenemase-producing Enterobacteriaceae (CPE) begin during hospitalization, there is limited data about community-onset (CO) infections caused by CPE. Our aim is to describe the frequency of CO infections caused by CPE as well as the clinical features of CO bloodstream infections (CO-BSIs).

Methods. This study includes retrospective case series of CO infections caused by CPE in a tertiary hospital from January 2010 to July 2014. Any clinical sample with a positive culture for CPE that had been ordered by primary care doctors or by doctors at the emergency room (ER) were classified as CO. Epidemiological and microbiological features of CO cases were assessed as were clinical features of CO-BSIs.

Results. Of 780 clinical samples with CPE, 180 were requested at the ER or by primary care doctors (22.9%), 150 of which were produced by Klebsiella pneumoniae (83.3%). The blaOXA-48 gene was detected in 149 isolates (82.8%) followed by the blaVIM gene, 29 (16.1%). Sixty-one patients (33.9%) had a prior history of CPE infection/colonization. Thirty-four of the 119 (28.6%) patients without prior history of CPE infection/colonization did not fulfill Friedman criteria for healthcare-associated infections (HAIs). Considering previous hospitalization of up to 12 months as a criterion for defining HAI, only 16 (13.4%) cases were identified as community-acquired infections. The most frequent positive sample was urine (133 of 180; 73.9%). Twenty-one (11.7%) patients had a BSI, 9 of them secondary to urinary tract infections (42.9%). Thirty-day crude mortality among patients with BSI was 23.8% (5 of 21).

Conclusions. Community-onset infections caused by CPE are an important subgroup of all CPE infections. The urinary tract is the main source. Bloodstream infections accounted for more than 10% of the cases.

Keywords. bloodstream infections; carbapenemase-producing Enterobacteriaceae; community-onset infections; epidemiology.

Carbapenems are among the most potent, broadest-spectrum antimicrobials. As such, they are useful for the empirical therapy of severe infections potentially caused by several multidrug-resistant microorganisms (MDROs) and for targeted therapy when MDROs are isolated in patients with severe infections. Infections caused by carbapenem-resistant Gram-negative bacteria have significantly increased in recent years, especially due to carbapenemase-producing Enterobacteriaceae (CPE) [1]. Patients with severe infections caused by CPE face alarming mortality rates because they are currently one of the main challenges for healthcare institutions and public health authorities [2].

The epidemiology of carbapenemases, which have spread worldwide, is complex. In Spain, the interregional spread of CPE—mainly OXA-48-producing Klebsiella pneumoniae—has occurred since 2011 [3, 4]. In our institution, we first detected CPE in 2005: VIM-producing K pneumoniae. Since then, we have observed a multispecific and polyclonal pattern of VIM-producing Enterobacteriaceae [5]. In December 2010, an outbreak of OXA-48-producing K pneumoniae started in our hospital. After the outbreak had begun, we detected a hyperendemic pattern of patients with OXA-48-producing Enterobacteriaceae in clinical or surveillance samples [6]. Since 2013, we have detected 7 patients infected or colonized with NDM-producing Enterobacteriaceae [7]. KPC-producing Enterobacteriaceae have been described sporadically.

Although CPE infections have been found predominantly in healthcare and nosocomial settings, the frequency of community-onset (CO) infections by these microorganisms is expected to increase, as reported for extended-spectrum β-lactamases.
Not only do carbapenemases have a significant capability for horizontal transfer, but the clones on which carbapenemases settle are frequently successful from the epidemiological standpoint. In addition, gastrointestinal colonization can last for months [8–10]. In this scenario, CO infections can either arise in patients who were colonized during a previous hospitalization or after significant contact with healthcare or represent true community-acquired infections, which is a step further in the spread of CPE. Unfortunately, CO infections caused by other multidrug-resistant Enterobacteriaceae have been repeatedly associated with a delay in appropriate antimicrobial therapy and, subsequently, with poorer outcomes [11, 12].

Despite ongoing antimicrobial resistance surveillance programs, there is very limited information about the epidemiology of CO infections caused by CPE [13]. The proportion of infections caused by CPE that have a CO is not well known, nor is the proportion of these infections that are truly community-associated (CA), representing transmission in the community. From a clinical standpoint, there is little information on the burden of CO CPE infections and their presentation and severity. Case series of CPE BSI have seldom included CO infections [8].

To assess the frequency and epidemiological features of CO infections caused by CPE, we conducted a 4-year retrospective study in our center. In addition, we focused on the clinical features of bloodstream infections (BSIs) caused by CPE.

**METHODS**

**Setting**

Hospital Universitario La Paz (HULP) is a 1200-bed tertiary hospital of the Spanish National Health System. It is the reference hospital for a mixed urban and periurban population of approximately 500,000 people in northern Madrid. Twenty public primary care practices located in the hospital reference area share the same microbiology laboratory.

**Inclusion Criteria**

Consecutive, nonhospitalized, adult patients (≥18 years old) with CPE isolated from clinical samples in the HULP Microbiology Department from January 2010 to July 2014 were included. Patients were considered to be nonhospitalized at the time the sample was obtained if the sample was requested by a physician from the emergency room (ER) or from primary care practices. For epidemiological purposes, only the first CPE isolated in each patient was considered. For clinical purposes, all patients with CO BSIs caused by CPE were included.

**Bacterial Isolates and Microbiological Workup**

Enterobacteriaceae isolates were suspected of producing a carbapenemase if imipenem and/or meropenem minimum inhibitory concentrations (MICs), determined by automated broth microdilution, were >1 mg/L and/or >0.5 mg/L in the case of ertapenem. For all suspected isolates, a Modified Hodge Test (MHT) was performed. All positive MHTs were confirmed by polymerase chain reaction (PCR) (OXA-48-, VIM-, KPC-, NDM-specific primers). The genetic relationships between the isolates of OXA-48-producing K pneumoniae were determined by clone-specific PCR, multilocus sequence typing (MLST), and by automated repetitive sequence-based PCR using the DiversiLab (bioMérieux) system [14, 15].

**Clinical and Epidemiological Data**

We assessed the demographic and epidemiological features related to the first episode of CPE in clinical samples obtained from nonhospitalized patients. Age, gender, the existence of previous isolates of CPE, hospitalizations (≥48 hours) within 1 year, residence in a nursing home, and the receipt of hemodialysis and home care were reviewed. For this purpose, HULP and regional healthcare health information systems were reviewed. Primary Care medical records were available through an online electronic medical records platform provided by the Comunidad de Madrid regional healthcare system. This platform provides information on every visit paid to primary care doctors (PCDs) or nurses within the geographical area tributary to our Microbiology Laboratory. Information regarding antibiotics prescribed by PCDs was available through this system. In addition, for all episodes of CO CPE BSI, demographic characteristics, comorbidity, clinical presentation, source of infection, recent exposure to antimicrobials, and clinical outcomes were retrieved from the medical records by the investigators.

**Definitions**

Episodes in patients with CPE CO infections and no history of infection/colonization during previous hospitalizations were primarily classified according to Friedman [16] as healthcare-associated (HCA) if any of the following criteria were present: ≥48-hour hospital admission during the previous 90 days; receipt of hemodialysis, intravenous medication, or home wound care in the previous 30 days; and residence in a nursing home or long-term care facility. Given the duration of gastrointestinal colonization by CPE, an alternative definition of HCA, increasing the time since the last hospitalization to 1 year, was used as well (modified Friedman’s [16] criteria). For BSI, the Charlson Comorbidity Index [17] and McCabe-Jackson [18] classification (nonfatal, ultimately fatal, or rapidly fatal) were used to evaluate comorbidity and prognosis. Acute severity of illness was evaluated with the Pitt bacteremia score [19]. Sepsis level was graded as sepsis, severe sepsis, or septic shock, following the definition of systemic inflammatory response syndrome [20]. The source of bacteremia was determined according to the clinical presentation or by the evidence of an identical strain cultured near to, or on the same date as, the onset of BSI from other body sites. If the source of bacteremia could not be identified, it was classified as primary bacteremia. Anti-infective therapy was considered (1) microbiologically appropriate if the patient received at least 1 active agent against the isolate (MIC within the susceptible range) and (2) clinically...
adequate if the patient received a combination of 2 active antibiotics, at the right dose and route according to the source of infection. Use of imipenem or meropenem if MIC was ≤8 mg/L was considered adequate if high-dosed and associated with a second microbiologically active agent [21].

Statistics
Mean, median, and range were calculated when appropriate. Categorical variables were compared using the χ² test. Statistical software program SPSS, version 17.0 for Windows (SPSS, Chicago, IL) was used to perform all analyses.

Ethic
The HULP Institutional Review Board evaluated and approved the study protocol. Given its observational retrospective design, informed consent was waived.

RESULTS
During the study period, 1866 patients infected and/or colonized by CPE were detected in our institution. Of these, 780 had CPE in at least 1 clinical sample. Carbapenemase-producing Enterobacteriaceae were detected in clinical samples of 180 non-hospitalized patients (23.1%). Sixty-one samples (33.9%) had been requested by PCDs and 119 (66.1%) by the ER doctors, representing 0.36% and 2.96% of all patients from whom Enterobacteriaceae were isolated, respectively (Tables 1 and 2).

The most frequent carbapenemase identified in CO infections was OXA-48 (149 of 180; 83.3%), followed by VIM (29 of 180; 16.1%). The most frequent CPE-positive sample was urine (133 of 180; 73.9%), followed by blood (21 of 180; 11.7%). Klebsiella pneumoniae accounted for the majority (149 of 180; 82.8%) of CPE isolates. Most (119 of 180; 66.1%) of the nonhospitalized patients with positive cultures for CPE had no prior history of CPE colonization or infection, although this proportion decreased during the study period, from 83.3% in 2010 and 2011 to 51.1% in 2014 (P = .017). The main epidemiological features of patients with CPE in clinical samples requested by PCDs or at the ER are summarized in Tables 1 and 2, respectively. Among the patients without prior history of infection/colonization by CPE, 34 of 119 (28.6%) did not fulfill any of the Friedman [16] criteria and thus would not be considered to be HCA (Figure 1). Nevertheless, if the interval since the last significant hospitalization was increased to 12 months, only 16 of 119 (13.4%) would not be considered to be HCA. In all of them, CPE harbored OXA-48. Of these, at least 2 patients with CO OXA-48-producing K pneumoniae urinary tract infections were household members of individuals infected with or colonized by CPE or who had been hospitalized in units with ongoing CPE transmission as their sole healthcare relationship.

Among the 150 cases of carbapenemase-producing K pneumoniae, 124 were OXA-48 producers. Of these, 54 were typed and found to belong to 6 different clones: 16 isolates belonged to ST405, 31 to ST11, 4 to ST323, and the remaining 3 belonged to 3 different clones by Diversilab but were not typed by MLST. These 3 predominant clones matched the major clones detected in hospital samples. Cumulative curves of ST405 and ST11 detected in samples obtained from nonhospitalized patients paralleled those found in the hospital (Figure 2).

Twenty-one patients had a CO CPE BSI. All blood cultures were requested at the ER. Fifteen episodes (71.4%) were caused by K pneumoniae, 4 (19%) by Serratia marcescens, 1 by

| Table 1. Frequency, Distribution, and Main Epidemiological Features of Clinical Isolates of CPE in Microbiological Samples Requested by Primary Care Physicians From a Healthcare District in Northern Madrid |
|---------------------------------|------|------|------|------|------|------|
| **Enterobacteriaceae**          | 2010 | 2011 | 2012 | 2013 | 2014 (January–July) | Total |
| KP (KP/Enterobacteriaceae %)    | 3712 | 3630 | 3352 | 3905 | 2432 | 17031 |
| CPE (CPE/Enterobacteriaceae %) | 496 (13.4) | 451 (13.4) | 552 (14) | 327 (13.4) | 13 (14) | 2279 (13.4) |
| CP-KP (CP-KP/CPE %)            | 1 (0.03) | 6 (0.17) | 15 (0.45) | 16 (0.41) | 20 (0.87) | 61 (0.36) |
| OXA                            | 9 (0.25) | 4 (0.11) | 14 (0.39) | 13 (0.32) | 12 (0.67) | 46 (0.26) |
| VIM                            | 2 (0.05) | 4 (0.11) | 15 (0.40) | 12 (0.29) | 20 (0.87) | 50 (0.28) |
| KPC                            | 2 (0.06) | 0 (0) | 5 (0.14) | 15 (0.36) | 21 (0.87) | 57 (0.32) |
| Other samples                   | 3 (0.08) | 1 (0) | 0 (0) | 1 (0) | 2 (0.09) | 4 (0.02) |
| Prior CPE colonization/Infection (Prior CPE/CPE %) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 8 (3.48) | 14 (23) |
| Healthcare-associated* (Friedman [16] criteria) (%) | 1 (100) | 4 (66.7) | 7 (58.3) | 8 (66.7) | 7 (46.7) | 27 (57.4) |
| Hospitalization within 90 d     | 1 (100) | 0 (0) | 1 (100) | 0 (0) | 4 (50.0) | 11 (52.4) |
| Hemodialysis                    | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Outpatient IV therapy           | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Home wound care                 | 0 (0) | 1 (100) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Nursing home/LTCF               | 0 (0) | 1 (100) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Healthcare-associated* (modified criteriab) (%) | 1 (100) | 5 (83.3) | 11 (84.6) | 9 (75) | 11 (84.6) | 37 (78.7) |

Abbreviations: CPE, carbapenemase-producing Enterobacteriaceae; KP, Klebsiella pneumoniae; CP-KP, carbapenemase-producing K pneumoniae; IV, intravenous; LTCF, long-term care facility.

* Among patients without prior history of CPE infection/colonization.

b Includes history of hospitalization in the previous year.
Table 2. Frequency, Distribution, and Main Epidemiological Features of Clinical Isolates of CPE in Microbiological Samples Requested at the Emergency Room of a Tertiary Academic Center in Northern Madrid

|                         | 2010 | 2011 | 2012 | 2013 | 2014 (January–July) | Total |
|-------------------------|------|------|------|------|---------------------|-------|
| Enterobacteriaceae      | 468  | 714  | 965  | 1108 | 761                 | 4016  |
| KP (KP/Enterobacteriaceae %) | 54 (11.5) | 99 (13.9) | 136 (14.1) | 192 (17.3) | 118 (15.5) | 599 (14.9) |
| CPE (CPE/Enterobacteriaceae %) | 1 (0.21) | 12 (1.68) | 33 (3.42) | 49 (4.42) | 24 (3.15) | 119 (2.96) |
| CP-KP (CP-KP/CPE %)     | 0 (0) | 12 (100) | 27 (81.8) | 40 (81.6) | 21 (87.5) | 100 (84) |
| OXA                     | 0    | 11   | 25   | 45   | 22                  | 103   |
| VIM                     | 1    | 1    | 8    | 4    | 2                   | 15    |
| VIM                     | 1    | 0    | 0    | 1    | 1                   | 1     |
| Urine                   | 1    | 7    | 21   | 31   | 16                  | 76    |
| Blood                   | 0    | 3    | 8    | 6    | 4                   | 21    |
| Other samples           | 0    | 2    | 4    | 12   | 4                   | 22    |

Prior CPE colonization/Infection (Prior CPE/CPE %) 0 (0) 3 (25) 9 (27.3) 20 (40.8) 15 (62.5) 47 (39.5)

Healthcare-associated* (Friedman [16] criteria) (%) 1 (100%) 9 (100) 17 (70.9) 25 (86.2) 6 (66.7) 58 (90.6)

Hospitalization within 90 d 1 9 20 21 5 56

Hemodialysis 0 1 2 1 0 4

Outpatient IV therapy 0 2 8 7 0 17

Home wound care 0 0 0 0 0 0

Nursing home/LTCF 1 1 4 7 1 14

Healthcare-associated* (modified criteria) (%) 1 (100%) 9 (100) 22 (91.7) 27 (93.1) 7 (77.8) 66 (91.7)

Abbreviations: CPE, carbapenemase-producing Enterobacteriaceae; KP, Klebsiella pneumoniae; CP-KP, carbapenemase-producing K pneumoniae; IV, intravenous; LTCF, long-term care facility.

* Among patients without prior history of CPE infection/colonization.

*b Includes history of hospitalization in the previous year.

Figure 1. Flow chart of patients included in the study and distribution of factors associated with healthcare among them. Abbreviations: BSI, bloodstream infection; CPE, Carbapenemase-producing Enterobacteriaceae; HCA, healthcare-associated; HULP, hospital universitario La Paz; LTCF, long-term care facility.
Enterobacter cloacae, and 1 by Klebsiella oxytoca. The blaOXA-48 gene was identified in 15 (71.4%) isolates, and the blaVIM gene was identified in the remaining 6 (28.6%). Median age at onset of infection was 77 (range, 49–90), and most of the patients were male (18 of 21; 85.8%). Median Charlson score was 4 (range, 1–11). Seven (33.3%) were oncohematological patients, and 6 (28.6%) had other types of cancer. Prior rectal colonization was known in 5 (23.8%) patients, and the median time from rectal colonization to infection was 11 days (range, 7–114 days). Systemic antibiotic exposure within 90 days before the onset of infection was documented in 15 (71.4%) patients, whereas hospitalization for more than 48 hours was observed in 13 (62%) patients. Median Pitt score at onset of infection was 2 (range, 0–4). Three patients (14.3%) were in septic shock at the onset of infection, and 5 patients had severe sepsis (23.8%). Nine (42.9%) BSIs had a urinary source, whereas 2 patients each (9.5%) had a surgical site, catheter, or intra-abdominal source, respectively. In 4 (19%) patients, bacteremia was apparently primary. Thirty-day crude mortality was 23.9% (5 of 21). Eighteen patients received appropriate therapy in a median time of less than 1 day (0–3 days). Sixteen patients (16 of 21) received adequate therapy in a median time of 3 days (0–6 days) since onset of bacteremia. Detailed features of patients with CO BSI caused by CPE are presented in Table 3.

**DISCUSSION**

We found that more than 20% of all clinical samples positive for CPE at our institution were obtained from nonhospitalized patients. This finding depicts the existence of a pool of nonhospitalized patients at risk of developing infections by CPE, as a consequence of persistent gastrointestinal colonization by these microorganisms. It is worth noting that this pool of patients colonized by CPE can be considered one of the main reservoirs for the spread of these resistance genes in the community. In addition, because these patients might need further hospitalization, they could be responsible for further transmission within the hospital too. Given their epidemiological relevance and the paucity of available information about CO CPE infections, antimicrobial resistance surveillance programs should probably increase their focus on this epidemiological setting.

It is remarkable that almost 30% of patients with CO CPE infections did not fulfill any of the Friedman [16] criteria for HCA infections and would therefore be classified as CA. Because prolonged gastrointestinal colonization can occur, it is reasonable to increase the interval between infection onset and previous hospitalization to better identify HCA CPE infections. Indeed, if the previously mentioned interval was increased to 1 year, almost 90% of CO CPE infections in our series would be considered to be HCA. Therefore, from an epidemiological perspective, our study suggests that the most widely used criteria for classifying infections as HCA might not be precise enough in the case of CPE.

Even after increasing the interval between the onset of infection and prior hospitalization, 10% of CO CPE infections—all of which were caused by OXA-48-producing *K pneumoniae*—would not fulfill the criteria for HCA. It is interesting to note that 2 of the patients without any classic risk factors for HCA infections had been taking care of other patients or had close contact in an environment where CPE were circulating and, thus, should be considered to have been transmitted within the household. Further research into the risk of transmission of CPE to household contacts (human or animal) is definitely needed.

Overall, OXA-48- and VIM-producing Enterobacteriaceae were detected in a relatively similar number of patients at our institution. However, among CO CPE infections, the predominance of OXA-48-producing *Enterobacteriaceae* is surprising. Whether this predominance is related to a survival advantage of *blaOXA-48* gene carriers, to the high horizontal transfer of the *blaOXA-48* gene, or other unidentified reasons remains unknown and also deserves further research [22–24].

To the best of our knowledge, this is the largest series of CO CPE BSIs reported to date. From a clinical perspective, although the most frequent sample among nonhospitalized individuals with suspected CPE infections was the urine, BSIs accounted for more than one third of all of the episodes in which CPE were identified in clinical samples requested at the ER. Indeed, more than 15% of all CPE BSIs in our institution had a CO, which is higher than that which has been described by Daikos et al [8]. Among patients with BSI, the most frequently identified source was the urinary tract. Nevertheless, as recently
| Age/ Gender (M/F) | Comorbidity | Neutropenia | Prior Infection/ Colonization | Severity at Presentation (Pitt Score) | Source | Microorganism (Carbapenemase) | Empiric Therapy | Definitive Therapy | Time to Appropriate Therapy | Time to Adequate Therapy | Death at 30 d | Death at 6 months |
|------------------|-------------|-------------|-----------------------------|-------------------------------------|--------|-----------------------------|----------------|-------------------|--------------------------|--------------------------|----------------|----------------|
| 1                | 63/M        | Lymphoma (allo-BMT) | Y                           | N                                   | Septic shock (2) | Intra-abdominal | Klebsiella pneumoniae (VIM) | Amikacin | Tigecycline + amikacin | 0                         | 0                        | N              | Y (90 d)              |
| 2                | 76/M        | Diabetes   | N                           | N                                   | Sepsis               | Respiratory | Klebsiella oxytoca (VIM) | Meropenem + amikacin | Meropenem + ciprofloxacin | 0                         | 0                        | N              | N                      |
| 3                | 56/M        | Lymphoma   | N                           | Y                                   | Sepsis (3)           | Catheter    | Serratia marcescens (VIM) | Meropenem | Meropenem + amikacin | 0                         | 4                        | N              | N                      |
| 4                | 64/M        | Lymphoma, HIV, diabetes, COPD | N                           | N                                   | Severe sepsis (2) | Urinary     | K pneumoniae (OXA-48) | Meropenem | Meropenem + colistin | 0                         | 6                        | N              | N                      |
| 5                | 51/M        | Chronic kidney disease (hemodialysis), diabetes | N                           | N                                   | Sepsis               | Intra-abdominal | K pneumoniae (OXA-48) | Meropenem | Meropenem + amikacin | 0                         | 3                        | N              | Y (32 d)              |
| 6                | 77/M        | Chronic kidney disease, Connective-tissue disease | N                           | N                                   | Severe sepsis (0) | Skin and soft tissue | K pneumoniae (OXA-48) | Amikacin | Meropenem + tigecycline | 1                         | 6                        | N              | Y (36 d)              |
| 7                | 79/M        | Coronary artery disease, COPD dementia | N                           | N                                   | Sepsis (3)           | Skin and soft tissue | K pneumoniae (OXA-48) | Meropenem | Meropenem + levofloxacin | 1                         | 2                        | Y (14 d)       |
| 8                | 49/F        | Cancer     | N                           | N                                   | Sepsis (1)           | Catheter    | Enterobacter cloacae (VIM) | Cefepime | No appropriate therapy | No appropriate therapy | No adequate therapy | N              | N                      |
| 9                | 90/M        | Cancer     | N                           | N                                   | Sepsis (2)           | Urinary     | K pneumoniae (OXA-48) | Meropenem | No adequate therapy | No adequate therapy | Y (14 d)       |
| 10               | 78/M        | Cancer, cerebrovascular disease, chronic kidney disease | N                           | N                                   | Severe sepsis (1) | Urinary (prostatitis) | K pneumoniae (OXA-48) | Meropenem + amikacin | 1                         | 1                        | N              | N                      |
| 11               | 65/M        | Cancer, diabetes, cerebrovascular disease | N                           | Y                                   | Severe sepsis (2) | Urinary     | K pneumoniae (OXA-48) | Meropenem | Meropenem + colistin | 0                         | 1                        | N              | N                      |
| 12               | 86/M        | Chronic renal disease | N                           | N                                   | Sepsis (1)           | Urinary     | K pneumoniae (OXA-58) | Meropenem | Meropenem + amikacin | 0                         | 1                        | N              | Y (39 d)              |
| 13               | 69/M        | Diabetes, chronic kidney disease | N                           | N                                   | Septic shock (2) | Urinary     | K pneumoniae (OXA-48) | Meropenem | Meropenem + amikacin | 1                         | 1                        | Y (19 d)       |
| 14               | 77/M        | Cancer     | Y                           | N                                   | Severe sepsis (4) | Primary     | S marcescens (OXA-48) | Meropenem | Meropenem | 0                        | No adequate therapy | Y (1 d)        |
| 15               | 88/F        | Lymphoma   | N                           | N                                   | Sepsis (2)           | Primary     | K pneumoniae (OXA-48) | Meropenem | No adequate therapy | N                        | N                      |
| 16               | 82/M        | Lymphoma, diabetes, COPD | Y                           | N                                   | Sepsis (1)           | Primary (febrile neutropenia) | S marcescens (VIM) | Meropenem | Ciprofloxacin + gentamicin | 1                         | 2                        | N              | Y (45 d)              |
| 17               | 59/M        | Lymphoma   | Y                           | Y                                   | Sepsis (2)           | Primary (febrile neutropenia) | K pneumoniae (VIM) | Meropenem | Meropenem + colistin | 0                         | 1                        | Y (24 d)       |
| 18               | 82/F        | Lymphoma   | Y                           | Y                                   | Septic shock (4) | IV catheter | S marcescens (VIM) | Meropenem | Aztreonam + ciprofloxacin | 0                         | 3                        | N              | N                      |
| 19               | 89/M        | Cerebrovascular disease, chronic kidney disease | N                           | N                                   | Sepsis (0)           | Urinary     | K pneumoniae (OXA-48) | Meropenem | Meropenem + amikacin | 0                         | 3                        | N              | N                      |
| 20               | 82/M        | Diabetes, COPD, Connective-tissue disease | N                           | N                                   | Sepsis (0)           | Urinary (prostatitis) | K pneumoniae (OXA-48) | Meropenem | Meropenem + amikacin | 0                         | 3                        | N              | N                      |
| 21               | 66/M        | Cancer, diabetes, chronic kidney disease | N                           | Y                                   | Sepsis (1)           | Urinary     | K pneumoniae (OXA-48) | Meropenem | Meropenem + amikacin | 1                         | 3                        | N              | Y (35 d)              |

Abbreviations: allo-BMT, allogeneic bone marrow transplant; COPD, chronic obstructive pulmonary disease; HIV, human immunodeficiency virus; IV, intravenous.
described, a significant proportion of BSIs did not have an identifiable source [2]. It is interesting to note that 30-day crude mortality in patients with CO CPE caused by CPE in our study was slightly over 20%, which is significantly lower than in most series of CPE BSIs reported to date [25]. We believe that observed mortality is accurate because we had proof of life of all patients classified as 30-day survivors (results of a blood test, radiological exam, or a nonmissed doctor’s appointment). The predominance of low-risk sources, such as urine, the existence of an ongoing antimicrobial stewardship program actively targeting CPE BSI, and host-related factors are circumstances that might have influenced the lower-than-expected 30-day crude mortality among patients with CO CPE BSI.

The main limitations of our study are derived from its retrospective design. Although it is unlikely that the most relevant epidemiological data (ie, Friedman [16] criteria) were missed, this could have happened with subtler epidemiological information, such as household or pet contacts. Unfortunately, this study does not provide definitive evidence of individual risk factors for these types of infections, because we did not use any control group. From the clinical standpoint, there are some limitations with regard to describing the features of the least severe infections because differentiating colonization from true infection retrospectively was expected to be problematic. A prospective design would, unquestionably, provide more relevant clinical data on this subset of CO CPE infections.

CONCLUSIONS

To summarize, CO CPE infections are an important subgroup of all CPE infections at our institution. Although most were HCA, no association with healthcare was found in almost one tenth of the cases, suggesting the transmission of CPE in the community. The most frequent CO CPE infections are urinary tract infections, which can present as BSIs. Our study emphasizes the importance of prompt identification and management of patients at risk of contracting these CO CPE infections.

Acknowledgments

Financial support. This study was supported by Instituto de Salud Carlos III (Spanish Ministry of Health) grants PI14/01832 (to J. R. P.-P.) and PI13/01218 (to J. M.).

Potential conflicts of interest. All authors: No reported conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest.

References

1. Pascual Á, Pintado V, Rodríguez Bano J, Miró JM. Carbapenemase-producing Enterobacteriaceae: the end of the antibiotic era? Enferm Infecc Microbiol Clin 2014; 32(suppl) 4:1–3.
2. Paño-Pardo JR, Villar SS, Ramos Ramos JC, Pintado V. Infections caused by carbapenemase-producing Enterobacteriaceae: risk factors, clinical features and prognosis. Enferm Infecc Microbiol Clin 2014; 32(suppl) 4:41–8.
3. Oteo J, Hernández JM, Espasa M, et al. Emergence of OXA-48-producing Klebsiella pneumoniae and the novel carbapenemases OXA-244 and OXA-245 in Spain. J Antimicrob Chemother 2013; 68:317–21.
4. Oteo J, Saer D, Bautista V, et al. Carbapenemase-producing Enterobacteriaceae in Spain in 2012. Antimicrob Agents Chemother 2013; 57:6344–7.
5. Cendejas E, Gómez-Gil R, Gómez-Sánchez P, Mingorance J. Detection and characterization of Enterobacteriaceae producing metallo-beta-lactamases in a tertiary-care hospital in Spain. Clin Microbiol Infect 2010; 16:181–3.
6. Paño-Pardo JR, Ruíz-Carrascoso G, Navarro C, et al. Infections caused by OXA-48-producing Klebsiella pneumoniae in a tertiary hospital in Spain in the setting of a prolonged, hospital-wide outbreak. J Antimicrob Chemother 2013; 68:89–96.
7. Seara N, Oteo J, Carrillo R, et al. Interhospital spread of NDM-7-producing Klebsiella pneumoniae belonging to ST437 in Spain. Int J Antimicrob Agents 2015; 46:169–73.
8. Dálois GL, Tsaousi S, Tsouvelakis LS, et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother 2014; 58:3232–8.
9. Tumbarello M, Treccarichi EM, De Rosa FG, et al. Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicenter study. J Antimicrob Chemother 2015; 70:231–43.
10. López-Cerezo L, Almirante B. Epidemiology of infections caused by carbapenemase-producing Enterobacteriaceae: reservoirs and transmission mechanisms. Enferm Infecc Microbiol Clin 2014; 32(suppl) 4:10–6.
11. Zimmerman FS, Assous MV, Bdolah-Abram T, et al. Duration of carriage of carbapenem-resistant Enterobacteriaceae following hospital discharge. Am J Infect Control 2013; 41:190–4.
12. Laupland KB, Church DL. Population-based epidemiology and microbiology of community-onset bloodstream infections. Clin Microbiol Rev 2014; 27:647–64.
13. Kaiser RM, Castanheira M, Jones RN, et al. Trends in Klebsiella pneumoniae carbapenemase-positive K. pneumoniae in US hospitals: report from the 2007–2009 SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis 2013; 76:356–60.
14. Healy M, Huang J, Bittner T, et al. Microbial DNA typing by automated repetitive-sequence-based PCR. J Clin Microbiol 2005; 43:199–207.
15. López-Camacho E, Rentero Z, Ruíz-Carrascoso G, et al. Design of clone-specific probes from genome sequences for rapid PCR-typing of outbreak pathogens. Clin Microbiol Infect 2014; 20:8091–3.
16. Friedman ND, Kaye KS, Stout JE, et al. Health care-associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann Intern Med 2002; 137:791–7.
17. Charlson ME, Pompei P, Alex KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40:373–83.
18. McCabe WR, Jackson G. Gram-negative bacteremia. Arch Intern Med Am Med Assoc 1962; 110:856–64.
19. Chow IW, Yu VL. Combination antibiotic therapy versus monotherapy for Gram-negative bacteremia: a commentary. Int J Antimicrob Agents 1999; 11:7–12.
20. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992;1644–55.
21. Rodríguez Bano J, Casneros JM, Cobos-Trigueros N, et al. Diagnosis and antimicrobial treatment of invasive infections due to multidrug-resistant Enterobacteriaceae. Guidelines of the Spanish Society of Infectious Diseases and Clinical Microbiology. Enferm Infecc Microbiol Clin 2015; 33:337.e1–337.e21.
22. Poirel L, Potron A, Nordmann P. OXA-48-like carbapenemases: the phantom menace. J Antimicrob Chemother 2012; 67:1597–606.
23. Woodford N, Turton JF, Livermore DM. Multiresistant Gram-negative bacteria: the role of high-risk clones in the dissemination of antibiotic resistance. FEMS Microbiol Rev 2011; 35:236–55.
24. Poirel A, Poirel L, Nordmann P. De-repressed transfer properties leading to the efficient spread of the plasmid encoding carbapenemase OXA-48. Antimicrob Agents Chemother 2014; 58:467–71.
25. Casneros JM, Cobos-Reino J, Pujol-Rojo M, et al. Guidelines for the diagnosis and treatment of patients with bacteremia. Guidelines of the Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. Enferm Infecc Microbiol Clin 2007; 25:111–30.